ImmunoGen ELAHERE wins accelerated FDA approval for ovarian cancer

ImmunoGen, Inc. has announced that its platinum-resistant ovarian cancer drug ELAHERE (mirvetuximab soravtansine-gynx) has been granted FDA accelerated